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Abstract
Background: Renal cell carcinoma accounts for 90 % of renal neoplasms and metastatic disease is common. One
third of newly diagnosed cases will have synchronous metastases at diagnosis and further 25–50 % will develop
metachronous disease.
Case Presentation: This study presents two new cases of gallbladder metastasis from renal cell carcinoma (RCC)
from our institution and reviews the published literature. The final cohort included 52 evaluable patients. M/F ratio
was 2:1 and median age was 62.5 years. Most patients were diagnosed incidentally after follow-up or staging
imaging for RCC. Of the patients with available histology, all except one were clear cell type (n = 39) and 92 % were
polypoid. Thirty-six patients demonstrated metachronous gallbladder metastasis with median disease-free interval
(DFI) from nephrectomy of 4 years. The most frequent site of metastasis was the contralateral kidney (46.7 %)
followed by the pancreas and lung. The median disease-free interval (DFS) after cholecystectomy was 37 months.
Three- and five-year OS rates were 74 and 62 %, respectively. Age younger than 45 years (p = 0.008) and DFI
<24 months (p = 0.049) were associated with decreased OS.
Conclusions: RCC metastasis to the gallbladder is associated with an unusual pattern of concomitant metastasis.
Symptoms are not common. Simple cholecystectomy is associated with increased OS and nil local or port site
recurrence. Young age and short DFI are associated with decreased OS.
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Background
Renal cell carcinoma accounts for approximately 3 % of
malignancies in adults and 90 % of renal neoplasms [1].
Metastatic disease is common, and one third of newly
diagnosed cases will have synchronous metastatic disease
at presentation. A further 25–50 % will develop meta-
chronous disease [2]. Latent distant metastasis is charac-
teristic of renal cell carcinoma (RCC) and can manifest
more than a decade after nephrectomy in about 10 % of
patients [3].
Clear Cell (CC) RCC is the most common type of
renal cancer, accounting for 75 % of all primary kidney
tumours. Similar to other malignancies, RCC may
undergo differentiation to more aggressive histological
types. Sarcomatoid transformation is present in 5 % of
RCC, although these do not in themselves represent a
distinct histological entity [4]. Spindle cell morphology,
similar to sarcomas, can occur in all types of RCC but is
most often seen in clear cell and chromophobe RCC [5].
These patients have an adverse stage stratified prognosis
with a median survival of 4–19 months [6].
The most common sites of metastasis of RCC are the
lung, bone, liver, adrenal gland, brain and contralateral
kidney but have been documented in nearly every organ.
Gallbladder involvement is reported in <1 % of cases.
The outcome for metastatic RCC is poor, bearing a
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5-year survival rate of approximately 5–10 %, but cura-
tive resection of metastasis in selected patients is known
to improve long-term survival [4, 7].
Materials and methods
The review of literature was based on a systematic
PubMed search to identify all published cases of RCC
metastasis to the gallbladder and including cases de-
scribed in the Japanese literature. The final analysis in-
cluded 52 patients, 2 from our institution and 50 from
previous published cases (Table 1, database available
in Additional file 1: Table S1). Four articles were ex-
cluded because of unavailability of content or omission
of basic information particularly sex, age and interval
between nephrectomy and the diagnosis of metachro-
nous gallbladder lesion. When available, the data was
collected to focus on demographics, histology and sta-
ging of the primary tumour, disease-free interval (DFI)
from nephrectomy, size and extent of invasion into the
gallbladder, presence of gallstones, disease-free survival,
adjuvant therapy, follow-up time, and outcome.
The two case reports presented resulted from a 5-year
retrospective search through The Royal Marsden Hospi-
tal’s histopathological archives from gallbladder speci-
mens. Data was collected through review of patient
history, operative notes, pathology reports, and medical
records after consent.
Statistical analysis
Statistical analysis was performed with the Statistical
Package of the Social Sciences (SPSS), version 17.0.
The primary endpoints of the study were DFI be-
tween resection of primary renal tumour and presen-
tation of metachronous gallbladder metastasis.
Overall survival (OS) was calculated from the date
of operation for the gallbladder metastasis to the
date of disease-related death and was censored at
the time of last follow-up for patients that were alive
or at the time of death when unrelated to the dis-
ease. The impact of clinicopathological characteris-
tics on OS was analysed using both the Kaplan-
Meier and univariate Cox regression methods. Sur-
vival outcomes between groups were compared with
the log-rank test.
A chi-square test, Mann-Whitney non-parametric
test and Fischer’s exact test were used when appropri-
ate for calculating the association between clinico-
pathological characteristics and interval between
resection of primary renal tumour and presentation of
metachronous gallbladder metastasis, recurrence or
disease-related death. A p value of less than 0.05 was
considered statistically significant.
Case 1
In February 2012, a 60-year-old female presented with a
urinary tract infection (UTI), right loin pain and haema-
turia. In spite of effective treatment of the UTI, the loin
pain persisted. Evaluation by biphasic enhanced CT con-
firmed the presence of a 4-cm hypo-attenuating mass
occupying the lower pole of the right kidney without in-
vasion of the major renal vein or cava and without
lymph node enlargement. A number of nodules highly
suggestive of metastasis were present in both lungs, the
largest measuring 6.5 mm. CA 19.9, CA 15.5 and CEA
were negative. The patient underwent an uneventful lap-
aroscopic right radical nephrectomy. Histology of the
specimen showed CC RCC Leibovich score 1, pT1aN0
and Fuhrman grade 3.
Follow-up CT scan after 2 months showed no recur-
rence and stability of the lung lesions, but the scan at
month 5 showed total regression of the pulmonary nod-
ules. Follow-up CTs every 6 months were unremarkable
until July 2014, when a gallbladder mass was revealed.
She had a further MRI, which showed a 2.5-cm intra-
luminal polypoid mass in the inferior wall of the gall-
bladder. A laparoscopic cholecystectomy was performed
and the patient was discharged the following day. Histo-
pathology reported a 30 × 20 mm polypoid submucosal
metastatic deposit of CC RCC with an extensively ulcer-
ated surface, composed of large nests and sheets of mod-
erately sized polygonal cells with delicate cell borders
and clear cytoplasm and central nucleus showing hyper-
chromasia without a prominent nucleolus (Fig. 1). The
polyp was confined to the gallbladder with no extension
into serosa. Immunohistochemistry showed the tumour
cells to strongly express PAX8, Vimentin, CAM5.2,
AMACR and EMA, focal E-cadherin expression with no
tumour expression of CD10, RCCAg, CK7, or CD117.
The patient did not receive adjuvant therapy and
remained disease-free after 2 months of follow-up.
Case 2
A 57-year-old male with a previous history of resected
melanoma from the right arm (T1a) presented with sud-
den onset of acute abdominal pain and macroscopic
haematuria in May 2011. A CT scan showed a 12 × 10 ×
8 cm mass in the left kidney extending into the hilum
consistent with RCC and a gallbladder polyp. A number
of bilateral small peripheral and sub-pleural pulmonary
nodules measuring less than 5 mm and of indeterminate
nature were present. In June 2011, the patient under-
went an open radical nephrectomy and adrenalectomy,
with an uneventful recovery. Pathology revealed a CC
RCC Fuhrman 4 with extensive sarcomatoid changes
and areas of necrosis, invading muscular veins of renal
sinus including the main renal vein but without invasion
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Table 1 Review of literature
Authors No. of cases Source
Jain 1 Saudi J Kidney Dis Transpl 2013 Jan;24(1):100–4
Zygulska 1 Pol PrzeglChir 2012 Jun;84(6):313–6
Robledo 1 OncolLett 2012 May;3(5):1136–1138
Zevallos Quiroz 1 Cir Esp 2014 Apr;92(4):295–6
Decoene 1 Case Rep Med 2011;2011:671645
Chung 4 UrolOncol 2012 Jul–Aug;30(4):476–81
Kawahara 1 Case Rep Oncol 2010 Jan 29;3(1):30–34
Fang. 4 Arch Pathol Lab Med 2010 Jul;134(7):1003–9
Shoji 1 OncolLett 2010 May;1(3):507–509
Patel 1 Cases J. 2009 Oct 29;2:172
Kücükakin 1 UgeskrLaeger 2009 Aug 24;171(35):2486–7
Sand 1 Eur J Med Res 2009;14:90–2
Moujahid 1 GastroenterolClinBiol 2008 Aug–Sep;32(8–9):788–9
Nojima 1 J HepatobiliaryPancreatSurg 2008;15(2):209–12
Hellenthal 1 IntUrolNephrol 2007;39(2):377–9
Pandey 1 Indian J Gastroenterol 2006 May–Jun;25(3):161–2
Ishizawa 1 Asian J Surg2006 Jul;29(3):145–8
Miyagi 1 RinshoHinyokika 2003;57:257
Limani 1 ActaChirBelg 2003 Apr;103(2):233–4
Park 1 Yonsei Med J 2003 Apr 30;44(2):355–8
Gekiya 1 Jpn J UrolSurg2002;15:67
Aoki 2 Surg Today 2002;32(1):89–92
Ueki 1 Shoukakigazou 2001;3:373
Kechrid 1 Saudi J Kidney Dis Transpl 2000 Oct–Dec;11(4):587–92
Brasseur 1 J Radiol 1999 Jul;80(7):739–40
Celebi 1 Int J Urol 1998 May;5(3):288–90
Sparwasser 1 UrolInt 1997;58(4):257–8
Uchiyama 1 Jpn J Gastroenterol 1997;94:68
Furukawa 1 AJR 1997;169:1466
Kakimoto 1 HinyoukiGeka 1996;9:875
Lombardo 1 J Ultrasound Med 1996 Oct;15(10):725–8
Fujii 1 RinshoHinyokika 1995;49:405
King 1 Urology 1995 Nov;46(5):722–5
Pagano 1 Urology 1995 May;45(5):867–9
Coşkun 1 ActaChirBelg 1995;95:56
Naggler 1 Dig Dis Sci 1994 Nov;39(11):2476–9
Fullarton 1 Urology 1991 Aug;38(2):184–6
Golbey 1 Clin Imaging 1991 Oct–Dec;15(4):293–5
Satoh 1 Dig Dis Sci 1991 Apr;36(4):520–3
Terashima 1 Jpn J GastroenterolSurg 1990;23:1952
Harder 1 UgeskrLaeger 1983 Oct 17;145(42):3261
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of perinephric fat. All nodes were negative for malig-
nancy, staging the tumour as pT3bN0.
The next month, the patient experienced two episodes
of severe upper abdominal pain, nausea and vomiting
which completely subsided after administration of intra-
venous morphine, accompanied by unremarkable CT
emergency scans. He had a Barium swallow test and an
upper gastrointestinal endoscopy, both of which were
normal. On the third episode of acute abdominal pain in
July, he finally underwent a laparoscopic cholecystec-
tomy with relief of symptoms. Histopathology revealed a
22 × 15 × 8 mm polyp with normal mucosa composed of
nested/alveolar pattern of moderate-sized polygonal cells
with clear cytoplasm and well-defined cytoplasm bor-
ders, round central nuclei with a moderate degree of nu-
cleolar prominence, occasionally multinucleated, with
fine fibro-vascular septae present within thin wall vessels
and an admixture of inflammation and foamy macro-
phages at the periphery of the polyp. Immunohistochem-
istry showed these cells to express AE1/AE3, Vimentin,
CD10 and RCCAg with no expression of S100 or CEA,
consistent with the diagnosis of metastatic CC RCC.
The patient was followed up in an outpatient clinic ac-
companied by CTs at 3, 6 and 12 months post-op and
annually thereafter. The bilateral lung lesions remained
stable without adjuvant treatment, and the patient
remained disease-free until date (total follow-up of
38 months).
Results of literature review
Patient’s relevant primary tumour and gallbladder metas-
tasis characteristics are shown in Table 2. There was a
predominance of male patients (67.3 %), and the median
age at presentation of gallbladder metastasis was
62.5 years old (range 39–84). Of the 34 cases with initial
staging available, 19 demonstrated stage 4 disease
(55.9 %): 9 due to a single synchronous gallbladder me-
tastasis, 7 with other synchronous metastasis and 3 with
metachronous gallbladder involvement.
In most of the cases, the diagnosis was made inci-
dentally during a radiographic exam for staging or
on follow-up (74.4 %, n = 39). When symptomatic,
the majority of cases presented with acute or chronic
biliary symptoms. Of the cases with available path-
ology of the gallbladder RCC metastasis, all except
one were confirmed to be CC RCC, the remaining
being classified as RCC “type not specified”. The
gallbladder lesion was persistently polypoid/peduncu-
lated and intraluminal in 92 % of cases. The mean
size was 25 mm (range 8–75). Mucosal invasion was
evident in 65 %, and gallstones were present in only
15.6 % (7/45).
The majority of patients (36/52–69.2 %) demonstrated
metachronous gallbladder metastasis with a median DFI
of 4 years (range 0.25–27). DFI was not predicted by
sex, staging, incidental diagnosis vs. symptomatic dis-
ease, single vs. multiple metastases, macroscopic appear-
ance of gallbladder tumour, its extent of invasion in the
gallbladder wall or presence of gallstones.
The gallbladder was the sole site of metastatic disease
in 30/52 patients, and in 70 % of these patients pre-
sented as a metachronous lesion. Patients with multiple
sites of metastasis had the following pattern of disease:
contralateral kidney (46.7 %), pancreas (26.7 %), lung
Table 1 Review of literature (Continued)
Oikawa 1 GekaShinryo 1978;20:617
Botting 1 Mayo ClinProc 1963;38:225
Costa Neves 2 Current cases
Total 52
Fig. 1 Gallbladder specimen in low (a) and high-power field (b) showing the polyp confined to the gallbladder and composed of large nests and
sheets of moderately sized polygonal cells with delicate cell borders and clear cytoplasm
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(26.7 %), adrenal (20 %), skin (4.8 %), bones (4.8 %), IVC
(4.8 %), ovaries (4.8 %), bladder (4.8 %) and muscle
(4.8 %) (Table 3).
All patients had cholecystectomy and seven received
adjuvant therapy.
At a mean follow-up of 1.6 years (range 0.1–11) after
cholecystectomy, 52.6 % of the patients were alive with
no evidence of disease, 21.1 % were alive with disease,
21.1 % died from metastatic disease and 5.3 % died from
unrelated causes (Table 4). The median disease-free
interval (DFS) was 37 months (95 % confidence interval
24–48). Three- and five-year OS rates were 74 and 62 %,
respectively (Fig. 2). No patients developed local or port
site recurrence after simple cholecystectomy.
Univariate analysis (Table 5) revealed that age less than
45 years (hazards ratio (HR) 8.98; 95 % CI, 1.78–45.18;
Table 2 Patient, primary tumour and gallbladder metastasis characteristics
Parameter No. of patients (%) or median (range) No. of patients available for analysis











Gallbladder only 9 (17.3)
Gallbladder with other metastasis 7 (13.5)
Metachronous 36 (69.2)
Gallbladder only 21 (40.4)
Gallbladder with other metastasis 14 (26.9)
Unknown 1 (1.9)




Median size of gallbladder tumour, cm 25 (8–75) 44/52
Extent of invasion of gallbladder 20/52
Mucosa 13 (65)









Clear cell RCC 38 (97.4)
RCC type not specified 1 (2.6)
Patients with synchronous and metachronous gallbladder metastases are highlighted in italic
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p = 0.008) and DFI <24 months (HR 10.25; 95 % CI,
1.01–103.67; p = 0.049) were associated with decreased
OS (Figs. 3 and 4).
Discussion
Despite the great tendency of RCC to metastasize syn-
chronously or metachronously to numerous anatomical
sites, metastasis to the gallbladder is rare. Our review of
literature found 54 cases published by 43 papers dated
since 1963. Fifty cases were considered evaluable for this
report and with the addition of our two cases provided a
total cohort of 52 evaluable cases, thus representing the
most extensive and complete database on this subject to
date.
Unlike primary gallbladder cancer, RCC metastases to
the gallbladder show a clear male predominance and a
low incidence of concomitant gallstone disease [8, 9].
Moreover, the majority has a polypoid or pedunculated
morphology (46/50) whereas primary gallbladder cancer
has a diffuse wall thickening morphology [9].
The median DFI was 4 years, which is consistent with
the results found by Chung et al. in their review in 2012
[10]. We found a statistically significant decrease in OS
for patients younger than 45 years old and when the DFI
was less than 24 months.
The clear cell type was responsible for practically
all cases of metastasis of RCC to the gallbladder. It
is still not clear if this is due to the fact that CC
RCC is the most frequent type of RCC or whether
this type of metastasis is exclusive to clear cell type.
A sarcomatoid component generally implies a more
aggressive behaviour and bears a median survival of
Table 3 Presentation of all sites of metastasis
Parameters No. of patients (%) or median (range) No. of patients available for analysis
Metastatic disease presentation 51/52
Metastasis to only gallbladder 30 (58.5)
Metastasis to other sites 21 (41.2)
Sites of other metastases 15/21
Contralateral kidney (%) 7 (46.7)a
Pancreas (%) 4 (26.7)a
Lung (%) 4 (26.7)a
Adrenal (%) 3 (20)a
Skin (%) 1 (4.8)a
Bones (%) 1 (4.8)a
IVC (%) 1 (4.8)a
Ovaries (%) 1 (4.8)a
Bladder (%) 1 (4.8)a
Muscle (%) 1 (4.8)a
aPercent of 15 patients with known sites of other metastasis
Table 4 Intervention, follow-up and outcome
Parameters No. of patients (%) No. of patients available for analysis
Intervention
Cholecystectomy 51 (100) 51/52
Adjuvant therapy 7 (25.9) 27/52
Median follow-up time, years, median (range) 1.6 (0.1–11) 37/52
5-year OS, % 62 37/52
Median DFS, months (95 % CI) 37 (24–48) 26/52
Available outcome 38/52
No evidence of disease 20 (52.6)
Alive with metastasis 8 (21.1)
Death from metastasis 8 (21.1)
Non-cancerous death 2 (5.3)
Abbreviations: OS overall survival, DFS disease-free survival, CI confidence interval
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Fig. 2 Kaplan-Meier curve of disease-free survival (DFS) and overall survival (OS)
Table 5 Baseline clinicopathologic characteristics and their association with OS in univariate analysis
Parameters No. of patients (%) HR (95 % CI) p value No. of patients available for analysis
Sex 37/52
Male 25 (67.6) 1 (referent)
Female 12 (32.4) 1.37 (0.30–6.25) 0.682
Age 37/52
>45 33 (89.2) 1 (referent)
<45 4 (10.8) 8.98 (1.78–45.18) 0.008
Presentation 28/42
Asymptomatic 7 (25) 1 (referent)
Symptomatic 21 (75) 2.97 (0.59–14.77) 0.183
Timing 37/52
Synchronousa 14 (37.8) 1 (referent)
Metachronous 23 (62.2) 3.25 (0.39–27.10) 0.276
Staging 28/52
1 2 (7.1) b
2 4 (14.3) 1 (referent)
3 5 (17.9) 0.56 (0.05–6.33)
4 17 (60.7) 0.74 (0.30–1.83) 0.676
Single vs. multiple 36/52
Single 20 (55.6) 1 (referent)
Multiple 16 (44.4) 2.77 (0.50–15.28) 0.241
Interval from resection of primary to diagnosis of metastasis 23/35c
>24 months 17 (73.9) 1 (referent)
<24 months 6 (26.1) 10.80 (1.07–108.34) 0.043
Adjuvant chemotherapy
Yes 6 (28.6) 1 (referent) 21/52
No 15 (71.4) 2.28 (0.25–20.58) 0.461
Abbreviations: HR hazards ratio, CI confidence interval
aDiagnosis at the time of diagnosis of primary tumour
bAll cases are censored
cOnly
Statistically significant pvalue is highlighted in italic
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4–19 months after diagnosis [6], but our second case
patient had no recurrence throughout a follow-up
period of 38 months despite sarcomatoid histology.
The diagnosis of gallbladder lesion was predominantly
radiographic at initial staging or at follow-up after neph-
rectomy. The management of gallbladder polyps remains
controversial, but a review of literature published in
2012 stated that gallbladder polyps >10 mm, symptom-
atic, fast growing, sessile or wide-based; polyps with long
pedicles; any size of polyp in patients >50 years of age;
concurrent gallstones; polyps in the setting of primary
sclerosing cholangitis; or abnormal gallbladder
ultrasound are considered indications for surgery [11].
In the context of patients with a history of RCC, the sus-
picion of a metastasis should be considered.
A simple cholecystectomy is recommended for pedun-
culated tumours because gallbladder cancers of pedun-
culated type often remain within the mucosa, regardless
of the tumour size [12]. In our review, no patients with
RCC who underwent a simple cholecystectomy for a
metastatic polypoid lesion developed local recurrence
suggesting that a simple cholecystectomy is adequate
when a metastasis of RCC is suspected. Laparoscopic
cholecystectomy followed by a frozen section is appro-
priate when there is no evidence of serosal involvement
at laparoscopy [11], as port site metastases from gall-
bladder cancer have been reported [13].
It is interesting to notice that the presence of con-
comitant metastasis is different when there is gallbladder
involvement. In our cohort, involvement of the contra-
lateral kidney was the most frequent site of concomitant
disease, exhibiting a frequency of 46.7 %, contrasting
with the reported 5 % when gallbladder involvement is
absent [14]. Pancreatic and lung involvement showed a
frequency of 26.7 % each. This is intriguing, as the lung
is usually the most frequent site of RCC metastasis, oc-
curring in up to 60 % of patients [15], and pancreatic in-
volvement is reported in only 2 % of cases [16].
In our first case report, small bilateral lung lesions
were identified and the CT suggested these to be meta-
static disease. However, these lesions regressed com-
pletely 5 months after nephrectomy without adjuvant
treatment. The nature of these lesions remains uncer-
tain, because there was no tissue pathology confirmation
of metastatic disease. The initial stability of the lesions
and posterior total regression point towards a more
probable inflammatory nature, in spite of the absence of
respiratory symptoms, but spontaneous regression of
lung metastasis from RCC after nephrectomy is reported
[17, 18]. In our second case report, the patient also dem-
onstrated bilateral small lung lesions, some of them de-
scribed as inflammatory on CT. These lesions never
regressed but also did not progress throughout a 38-
month follow-up, suggesting the diagnosis of lung me-
tastasis as unlikely.
Several phase 3 randomized controlled studies are cur-
rently in place for adjuvant treatment with sunitinib, so-
rafenib, pazopanib, axitinib and everolimus. As the
results from these trials have not been published yet,
there is still no current evidence to support adjuvant
treatment after nephrectomy for RCC [1, 4].
Conclusions
Gallbladder metastasis from RCC is an uncommon
event. Most cases are asymptomatic, hence the import-
ance of radiological follow-up after nephrectomy. All
Fig. 3 Disease-free survival (DFI) between nephrectomy and
diagnosis of gallbladder metastasis and overall survival (OS) in
patients with metachronous gallbladder metastasis
Fig. 4 Age at diagnosis of gallbladder metastasis and overall
survival (OS)
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gallbladder polypoid lesions in patients with a history of
RCC mandate treatment, and simple cholecystectomy is
associated with increased OS and nil local or port site
recurrence published to date. The presence of gallblad-
der metastasis indicates an alteration in the pattern of
subsequent disease with relapse in the contralateral kid-
ney being the most common site of recurrence. Young
age and short DFI are associated with decreased OS.
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